These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 35499402)

  • 1. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19.
    Lockard R; Priest KC; Gregg J; Buchheit BM
    Subst Abus; 2022; 43(1):1150-1157. PubMed ID: 35499402
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
    Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
    JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects.
    Buchheit BM; Wheelock H; Lee A; Brandt K; Gregg J
    J Subst Abuse Treat; 2021 Dec; 131():108444. PubMed ID: 34098299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers.
    Sung ML; Black AC; Blevins D; Henry BF; Cates-Wessel K; Dawes MA; Drexler K; Hagle H; Molfenter T; Levin FR; Becker WC; Edelman EJ
    J Addict Med; 2022 Sep-Oct 01; 16(5):505-513. PubMed ID: 35020698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
    Ober AJ; Dopp AR; Clingan SE; Curtis ME; Lin C; Calhoun S; Larkins S; Black M; Hanano M; Osterhage KP; Baldwin LM; Saxon AJ; Hichborn EG; Marsch LA; Mooney LJ; Hser YI
    J Subst Use Addict Treat; 2024 Jan; 156():209194. PubMed ID: 37863356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
    J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
    Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences.
    Sousa JL; Raja P; Huskamp HA; Mehrotra A; Busch AB; Barnett ML; Uscher-Pines L
    J Addict Med; 2022 Nov-Dec 01; 16(6):702-708. PubMed ID: 35861337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical stakeholders' perceptions of patient engagement in outpatient medication treatment for opioid use disorder: A qualitative study.
    Poulsen MN; Roe SA; Asdell PB; Rahm AK; Berrettini W
    J Subst Use Addict Treat; 2024 Mar; 158():209250. PubMed ID: 38072381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA; Zhang L; Kim HM; Frost MC
    Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
    Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
    Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
    J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets.
    Hsu M; Jung OS; Kwan LT; Jegede O; Martin B; Malhotra A; Suzuki J
    J Subst Use Addict Treat; 2024 Feb; 157():209216. PubMed ID: 37981243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Threshold Buprenorphine via Community Partnerships and Telemedicine-Case Reports of Expanding Access to Addiction Treatment During COVID-19.
    Levander XA; Wheelock H; Pope J; Lee A; Hartmann K; Abuelkhair S; Gregg JL; Buchheit BM
    J Addict Med; 2022 Jan-Feb 01; 16(1):e56-e58. PubMed ID: 34374502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.